Loading
Adding pembrolizumab to gemcitabine-cisplatin, with gemcitabine continued as maintenance, lengthened survival in advanced biliary tract cancer by about two months, confirming the role of chemo-immunotherapy shown by TOPAZ-1.
Phase 3 placebo-controlled trial of 1,069 patients with untreated metastatic or unresectable biliary tract cancer randomised to pembrolizumab or placebo with gemcitabine-cisplatin, with gemcitabine continued beyond eight cycles.
Median overall survival was 12.7 versus 10.9 months (hazard ratio 0.83), with a consistent effect across subgroups and no new safety signals.
Pembrolizumab with gemcitabine-cisplatin is an approved first-line option for advanced biliary tract cancer alongside durvalumab-based therapy.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gemcitabine, Cisplatin.
Shares KEYNOTE-966, Intrahepatic cholangiocarcinoma, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin, Pembrolizumab.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin, Pembrolizumab.
Shares Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gemcitabine, Cisplatin.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin.